EBITDA: Income before interest, taxes, depreciation and amortization.
Nuvectis Pharma, Inc. (NVCT) had EBITDA of $-7.62M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.31M |
|
-- |
|
-- |
|
$7.62M |
|
$-7.62M |
|
$0.30M |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
$-7.31M |
|
$-7.62M |
|
|
EBITDA |
$-7.62M |
21.81M |
|
21.81M |
|
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$31.71M |
|
-- |
|
-- |
|
$31.71M |
|
$13.30M |
|
-- |
|
-- |
|
$13.30M |
|
$18.41M |
|
$18.41M |
|
$18.41M |
|
25.68M |
|
| Cash Flow Statement Financials | |
$-16.01M |
|
-- |
|
$29.11M |
|
$18.53M |
|
$31.63M |
|
$13.10M |
|
$6.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-39.72% |
|
-39.72% |
|
-23.07% |
|
-39.72% |
|
$0.72 |
|
$-0.73 |
|
$-0.73 |
|